Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "Cardia"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Effects of Polymorphisms of Innate Immunity Genes and Environmental Factors on the Risk of Noncardia Gastric Cancer
Jeongseon Kim, Young Ae Cho, Il Ju Choi, Yeon-Su Lee, Sook-Young Kim, Jung-Ah Hwang, Soo-Jeong Cho, Myeong-Cherl Kook, Chan Gyoo Kim, Young-Woo Kim
Cancer Res Treat. 2013;45(4):313-324.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.313
AbstractAbstract PDFPubReaderePub
PURPOSE
Increasing evidence suggests that polymorphisms in innate immunity genes are associated with Helicobacter pylori-induced inflammation and may influence susceptibility in developing noncardia gastric cancer. Therefore, we investigate the effect of polymorphisms of innate immunity genes and interactions with environmental factors in the Korean population.
MATERIALS AND METHODS
We genotyped four polymorphisms of TLR2 (rs1898830), TLR4 (rs10983755 and rs10759932), and CD14 (rs2569190) in a case-control study of 487 noncardia gastric cancer patients and 487 sex- and age-matched healthy controls. Polytomous logistic regression models were used to detect the effects of genetic polymorphisms and environmental factors, which were stratified by the histological type of gastric cancer.
RESULTS
TLR4 rs10983755 A carriers were found to have higher risk of intestinal-type noncarida gastric cancer than G homozygotes (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.01 to 1.97), but other genetic variants showed no association with the risk of noncardia gastric cancer. Among H. pylori-positive participants, smokers carrying TLR4 rs10983755 A had a higher risk of intestinal-type gastric cancer than nonsmoking TLR4 rs10983755 G homozygotes (OR, 4.28; 95% CI, 2.12 to 8.64). In addition, compared with tap water, other drinking water sources during childhood were found to be associated with the elevated risk of intestinal-type gastric cancer, and these associations were slightly stronger among TLR4 rs10983755 A carriers.
CONCLUSION
The genetic polymorphisms of innate immunity genes are associated with the development of intestinal-type noncardia gastric cancer and these associations may differ in accordance to an exposure to certain environmental factors.

Citations

Citations to this article as recorded by  
  • Association between Toll-like receptor 2 rs4696483 and rs1898830 polymorphisms and the risk of triple-negative breast cancer
    Rabeb M. Ghali, Sonia Zaied, Amira Daldoul, Perizat Kanabekova, Wassim Y. Almawi
    Gene.2024; 928: 148773.     CrossRef
  • Pathomorphological Manifestations and the Course of the Cervical Cancer Disease Determined by Variations in the TLR4 Gene
    Eglė Žilienė, Arturas Inčiūra, Rasa Ugenskienė, Elona Juozaitytė
    Diagnostics.2023; 13(12): 1999.     CrossRef
  • Ranking and Prioritizing Risk Factors for Gastric Cancer
    Ali Reza Yusefi, Shima Bordbar, Gholamhossein Mehralian, Kamran Bagheri Lankarani, Mohammad Khammarnia, Zahra Kavosi, Peivand Bastani
    The Open Public Health Journal.2023;[Epub]     CrossRef
  • Common variants in toll-like receptor family genes and risk of gastric cancer: a systematic review and meta-analysis
    Ayoub Al Othaim, Sulieman Ibraheem Shelash Al-Hawary, Hashem O. Alsaab, Sami G. Almalki, Mazin A. A. Najm, Ahmed Hjazi, Ali Alsalamy, Abbas Firras Almulla, Hamzeh Alizadeh
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer
    Xu Han, Tianyu Liu, Jiabao Zhai, Chang Liu, Wanyu Wang, Chuang Nie, Qi Wang, Xiaojie Zhu, Haibo Zhou, Wenjing Tian
    PeerJ.2022; 10: e13774.     CrossRef
  • Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate
    Debashis Dutta, Moumita Majumder, Ramesh Kumar Paidi, Kalipada Pahan
    Neurobiology of Disease.2021; 153: 105318.     CrossRef
  • Demethylation of the RB1 promoter concomitant with reactivation of TET2 and TET3 impairs gastric carcinogenesis in K19-Wnt1/C2mE transgenic mice
    Donghui Cao, Zhifang Jia, Yanhua Wu, Tongrong Su, Dan Zhao, Menghui Wu, Tetsuya Tsukamoto, Masanobu Oshima, Jing Jiang, Xueyuan Cao
    Life Sciences.2020; 263: 118580.     CrossRef
  • Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract
    Evagelia Spanou, Polyxeni Kalisperati, Ioannis S. Pateras, Alexandros Papalampros, Alexandra Barbouti, Athanasios G. Tzioufas, Athanassios Kotsinas, Stavros Sougioultzis
    Frontiers in Genetics.2017;[Epub]     CrossRef
  • Increased deaths from gastric cancer in communities living close to waste landfills
    Agostino Di Ciaula
    International Journal of Environmental Health Research.2016; 26(3): 281.     CrossRef
  • Correlation of Serum Levels of Endostatin with Tumor Stage in Gastric Cancer: A Systematic Review and Meta-Analysis
    Zheng-Hua Wang, Zhi-Tu Zhu, Xu-Yang Xiao, Jin Sun
    BioMed Research International.2015; 2015: 1.     CrossRef
  • Pattern-Recognition Receptors and Gastric Cancer
    Natalia Castaño-Rodríguez, Nadeem O. Kaakoush, Hazel M. Mitchell
    Frontiers in Immunology.2014;[Epub]     CrossRef
  • 12,406 View
  • 62 Download
  • 11 Crossref
Close layer
Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival
Sung-Hwan Kim, Mi Hyang Kwak, Sohee Park, Hak Jin Kim, Hyun-Sung Lee, Moon Soo Kim, Jong Mog Lee, Jae Ill Zo, Jung Sil Ro, Jin Soo Lee
Cancer Res Treat. 2010;42(4):210-216.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.210
AbstractAbstract PDFPubReaderePub
Purpose

We evaluated clinical outcomes after drainage for malignant pericardial effusion with imminent or overt tamponade.

Materials and Methods

Between August 2001 and June 2007, 100 patients underwent pericardiocentesis for malignant pericardial effusion. Adequate follow-up information on the recurrence of pericardial effusion and survival status was available for 98 patients.

Results

Recurrence of effusion occurred in 30 patients (31%), all of whom were diagnosed with adenocarcinoma. Multivariate analysis indicated that adenocarcinoma of the lung (hazard ratio [HR], 6.6; 95% confidence interval [CI], 1.9 to 22.3; p=0.003) and progressive disease despite chemotherapy (HR, 4.3; 95% CI, 1.6 to 12.0; p=0.005) were independent predictors of recurrence. Survival rates three months after pericardiocentesis differed significantly with the type of primary cancer; the rates were 73%, 18%, 90% and 30% in patients with adenocarcinoma of the lung, squamous cell carcinoma of the lung, breast cancer and other cancers, respectively.

Conclusion

Recurrence and survival of patients with malignant pericardial effusion are dependent on the type of primary cancer and response to chemotherapy. Patients with adenocarcinoma of the lung may be good candidates for surgical drainage to avoid repeated pericardiocentesis, but pericardiocentesis is considered effective as palliative management in patients with other cancers.

Citations

Citations to this article as recorded by  
  • Pericardiocentesis versus window formation in malignant pericardial effusion: trends and outcomes
    Jaeoh Lee, Kyu Kim, Seo-Yeon Gwak, Hyun-Jung Lee, Iksung Cho, Geu-Ru Hong, Jong-Won Ha, Chi Young Shim
    Heart.2024; 110(12): 863.     CrossRef
  • Pericardial effusion in oncological patients: current knowledge and principles of management
    S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto, P. Ameri
    Cardio-Oncology.2024;[Epub]     CrossRef
  • Malignant Pericardial Effusion: A Systematic Review
    Sarah E. Mudra, Danny Rayes, Ashwin K. Kumar, Jason Z. Li, Meredith Njus, Kevin McGowan, Charalampos Charalampous, Kazi A. Kalam, Alveena Syed, Muhammad Majid, Mary Schleicher, Ankit Agrawal, Abdullah Yesilyaprak, Allan L. Klein
    CJC Open.2024; 6(8): 967.     CrossRef
  • A Case Report of Video-assisted Thoracoscopic Pericardiectomy for Postpericardiotomy Recurrent Loculated Pericardial Effusion
    Hao-Wen Chang, Chen-Liang Tsai
    Journal of Medical Sciences.2024; 44(5): 231.     CrossRef
  • Recommendations of the Brazilian Society of Surgical Oncology for the Treatment of Neoplastic Pericardial Effusion
    Erlon de Avila Carvalho, Rachid Eduardo Noleto da Nobrega Oliveira, José Henrique Agner Ribeiro, Jefferson Luís Gross, Cezar Augusto Vendas Galhardo, Heládio Feitosa e Castro Neto, Giovana dos Santos, Reitan Ribeiro, Alexandre Ferreira Oliveira, Rodrigo N
    Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017
    Andrija Matetic, Bonnie Ky, Eric H. Yang, Phyo K. Myint, Muhammad Rashid, Shelley Zieroth, Timir K. Paul, Ayman Elbadawi, Mamas A. Mamas
    Cancer Medicine.2023; 12(5): 5471.     CrossRef
  • Breast Cancer Complicated by Cardiac Tamponade in a Patient With Neurofibromatosis Type 1
    Narek Hakobyan, Nosakhare Ilerhunmwuwa, Henry O Aiwuyo, Ephrem Sedeta, Ifeanyi Uche, Mustafa Wasifuddin, Jamal C Perry
    Cureus.2023;[Epub]     CrossRef
  • Cardiac tamponade
    Yehuda Adler, Arsen D. Ristić, Massimo Imazio, Antonio Brucato, Sabine Pankuweit, Ivana Burazor, Petar M. Seferović, Jae K. Oh
    Nature Reviews Disease Primers.2023;[Epub]     CrossRef
  • Peritoneal Carcinoma Unveiling a Hidden Threat: A Case of Malignant Pericardial Effusion
    Mohammed Abusuliman, Amr M Mohamed, Anas Mahmoud, Tala Beliani, Ibrahim M Ismail-Sayed
    Cureus.2023;[Epub]     CrossRef
  • Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
    Varsha Chiruvella, Asad Ullah, Islam Elhelf, Nikhil Patel, Nagla Abdel Karim
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis
    Talha Ahmed, Elie Mouhayar, Juhee Song, Efstratios Koutroumpakis, Nicolas L. Palaskas, Syed Wamique Yusuf, Juan Lopez-Mattei, Saamir A. Hassan, Peter Kim, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Ara A. Vaporciyan, Stephen Swisher, Anita Deswal, Ce
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Malignant Cardiac Tamponade: A Complication of Untreated Breast Cancer
    Mohamed Ramzi Almajed, Mark S Obri, Wasih Kamran, Abigail Entz
    Cureus.2022;[Epub]     CrossRef
  • High frequency ultrasound‐guided pericardiocentesis performed in the sitting position: A novel apical approach
    Lei Zhang, Xue‐Fei Zhang, Zhao Liu, Ying Liu, Cun‐Li Guo, Hua Shao, Bo Li, Cui Zhang, Hui Jing, Wen Cheng
    Clinical Cardiology.2021; 44(8): 1106.     CrossRef
  • How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia
    Robin Jacob, Nicolas L. Palaskas, Juan Lopez-Mattei, Saamir Hassan, Peter Kim, Teodora Donisan, Dinu Valentin Balanescu, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
    JACC: CardioOncology.2021; 3(3): 452.     CrossRef
  • Pericardial Effusion and Cardiac Tamponade: Etiology and Evolution in the Contemporary Era
    Claudio Martins de Queiroz, Juliano Cardoso, Felix Ramires, Barbara Ianni, Viviane Tiemi Hotta, Charles Mady, Paula de Cassia Buck, Ricardo Ribeiro Dias, Luciano Nastari, Fábio Fernandes
    International Journal of Cardiovascular Sciences.2021; 34(5 Supl 1): 24.     CrossRef
  • The Effect of Lenvatinib in Patients with Thyroid Cancer with Pericardial Metastasis, Which Can Cause Cardiac Tamponade
    Keiichiro Okano, Akihito Arai, Satomi Ozawa, Hiroki Morimoto, Gaku Omura, Takahiro Tsujikawa, Shigeru Hirano
    Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).2021; 124(11): 1525.     CrossRef
  • Clinico‐cytopathologic analysis of 574 Pericardial Effusion Specimens: Application of the international system for reporting serous fluid cytopathology (ISRSFC) and long‐term clinical follow‐up
    Min Jeong Song, Uiree Jo, Ji‐Seon Jeong, Kyung‐Ja Cho, Gyungyub Gong, Yong Mee Cho, Joon Seon Song
    Cancer Medicine.2021; 10(24): 8899.     CrossRef
  • Oncologic Emergencies—The Old, the New, and the Deadly
    Krishna Thandra, Zuhair Salah, Sanjay Chawla
    Journal of Intensive Care Medicine.2020; 35(1): 3.     CrossRef
  • Acute Myeloid Leukemia Presenting as Effusive Constrictive Pericarditis
    Andrew Lutz, Erik B. Schelbert, Konstantinos Lontos, James Rossetti, William Katz
    CASE.2020; 4(2): 97.     CrossRef
  • State-of-the-art Review: Interventional Onco-Cardiology
    Bala Pushparaji, Konstantinos Marmagkiolis, Cameron K. Miller, Moez K. Aziz, Dinu V. Balanescu, Teodora Donisan, Nicolas Palaskas, Peter Kim, Juan Lopez-Mattei, Mehmet Cilingiroglu, Saamir A. Hassan, Cezar A. Iliescu
    Current Treatment Options in Cardiovascular Medicine.2020;[Epub]     CrossRef
  • In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening
    Cheng-Guang Wu, Francesca Chiovaro, Alessandra Curioni-Fontecedro, Ruben Casanova, Alex Soltermann
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes
    Massimo Imazio, Marzia Colopi, Gaetano Maria De Ferrari
    Heart.2020; 106(8): 569.     CrossRef
  • Update on diagnosis and management of neoplastic pericardial disease
    Stefano Avondo, Alessandro Andreis, Matteo Casula, Massimo Imazio
    Expert Review of Cardiovascular Therapy.2020; 18(9): 615.     CrossRef
  • Oncological Emergencies from Pathophysiology and Diagnosis to Treatment: A Narrative Review
    Ameneh Jafari, Mostafa Rezaei-Tavirani, Maryam Salimi, Reza Tavakkol, Zahra Jafari
    Social Work in Public Health.2020; 35(8): 689.     CrossRef
  • Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion
    So Ree Kim, Eun Kyoung Kim, Jinhyun Cho, Sung-A Chang, Sung-Ji Park, Sang-Chol Lee, Seung Woo Park
    Journal of the American College of Cardiology.2020; 76(13): 1551.     CrossRef
  • Cancer prevalence, inpatient mortality and its predictors after pericardiocentesis
    İ̇dris Buğra ÇERİK, Ferhat DİNDAŞ, Emin KOYUN, İ̇brahim GÜL
    Cumhuriyet Medical Journal.2020;[Epub]     CrossRef
  • Neoplastic Pericardial Effusion: A Monocentric Retrospective Study
    Elisabetta Di Liso, Alice Menichetti, Maria Vittoria Dieci, Cristina Ghiotto, Alberto Banzato, Alessandra Bianchi, Giovanna Pintacuda, Marta Padovan, Floriana Nappo, Enrico Cumerlato, Federica Miglietta, Eleonora Mioranza, Giulia Zago, Luigi Corti, Valent
    Journal of Palliative Medicine.2019; 22(6): 691.     CrossRef
  • Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion
    Zhi Gang Hu, Ke Hu, Wen Xin Li, Fan Jun Zeng, Anna Halama
    PLOS ONE.2019; 14(5): e0217007.     CrossRef
  • Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma
    Bing Zhou, Lin Li, Dayou Shi, Tao Jiang, Guohui Xue, Jianping Xiong
    Indian Journal of Pathology and Microbiology.2019; 62(4): 566.     CrossRef
  • Cardiac Interventional Procedures in Cardio-Oncology Patients
    Teodora Donisan, Dinu Valentin Balanescu, Nicolas Palaskas, Juan Lopez-Mattei, Kaveh Karimzad, Peter Kim, Konstantinos Charitakis, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu
    Cardiology Clinics.2019; 37(4): 469.     CrossRef
  • Safety and Outcome of Percutaneous Drainage of Pericardial Effusions in Patients with Cancer
    Annop Lekhakul, Chalailak Assawakawintip, Eric R. Fenstad, Sorin V. Pislaru, Jeremy J. Thaden, Larry J. Sinak, Garvan C. Kane
    The American Journal of Cardiology.2018; 122(6): 1091.     CrossRef
  • The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion
    M. Szturmowicz, A. Pawlak-Cieślik, A. Fijałkowska, J. Gątarek, A. Skoczylas, M. Dybowska, K. Błasińska-Przerwa, R. Langfort, W. Tomkowski
    Supportive Care in Cancer.2017; 25(8): 2399.     CrossRef
  • Cardiovascular Complications of Cancer Therapy
    Hui-Ming Chang, Tochukwu M. Okwuosa, Tiziano Scarabelli, Rohit Moudgil, Edward T.H. Yeh
    Journal of the American College of Cardiology.2017; 70(20): 2552.     CrossRef
  • Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality
    Kirstine Kobberøe Søgaard, Dóra Körmendiné Farkas, Vera Ehrenstein, Krishnan Bhaskaran, Hans Erik Bøtker, Henrik Toft Sørensen
    Circulation.2017; 136(11): 996.     CrossRef
  • A Minimum Volume of More Than 60 mL Is Necessary for Adequate Cytologic Diagnosis of Malignant Pericardial Effusions
    Lisa M. Rooper, Syed Z. Ali, Matthew T. Olson
    American Journal of Clinical Pathology.2016; 145(1): 101.     CrossRef
  • Patient with Small Cell Lung Carcinoma and Suspected Right Upper Lobe Abscess Presenting with a Purulent Pericardial Effusion
    Khushboo Goel, Huthayfa Ateeli, Neil M. Ampel, Dena L’heureux
    American Journal of Case Reports.2016; 17: 523.     CrossRef
  • Surgical pericardial drainage in a series of 235 consecutive patients: an 8-year experience
    Ali Azari, Negar Manavifar, Veda Vakili, Leila Bigdelu
    Indian Journal of Thoracic and Cardiovascular Surgery.2016; 32(4): 250.     CrossRef
  • 2015 update on the diagnosis and management of neoplastic pericardial disease
    Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
    Expert Review of Cardiovascular Therapy.2015; 13(4): 377.     CrossRef
  • Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion
    Danielle El Haddad, Cezar Iliescu, Syed Wamique Yusuf, William Nassib William, Tarif H. Khair, Juhee Song, Elie N. Mouhayar
    Journal of the American College of Cardiology.2015; 66(10): 1119.     CrossRef
  • Haemodynamic Monitoring of Pericardial Effusion with Cardiac Tamponade in a Patient with Colorectal Cancer

    Journal of Anesthesia & Critical Care: Open Access.2015;[Epub]     CrossRef
  • Un traitement local ambitieux est-il envisageable en cas de métastases intrapéricardiques d’un cancer bronchique ?
    M. Riquet, C. Rivera, P. Mordant, É. Fabre
    Revue des Maladies Respiratoires.2014; 31(5): 439.     CrossRef
  • Les autres métastases
    A. Roche, C. Audigier-Valette
    Revue des Maladies Respiratoires Actualités.2014; 6(2): 173.     CrossRef
  • Análisis de las características clínicas, ecocardiográficas, microbiológicas y citopatológicas de derrames pericárdicos en un hospital de tercer nivel de atención
    José Martín Santa Cruz-Ruiz, Guillermo Sahagún-Sánchez, Diana González-Cabello, Nydia Sánchez-González
    Archivos de Cardiología de México.2014; 84(2): 86.     CrossRef
  • Infiltrative Cardiomyopathy and Pericardial Disease
    Syed Wamique Yusuf, Smita I. Negi, Daniel J. Lenihan
    Seminars in Oncology.2013; 40(2): 199.     CrossRef
  • Malignant Pericardial Effusion
    I. Burazor, M. Imazio, G. Markel, Y. Adler
    Cardiology.2013; 124(4): 224.     CrossRef
  • Prognostic relevance of pericardial effusion in patients with malignant diseases
    Tae-Dong Jeong, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi
    The Korean Journal of Hematology.2012; 47(3): 237.     CrossRef
  • Surgical properties and survival of a pericardial window via left minithoracotomy for benign and malignant pericardial tamponade in cancer patients
    Sezai Celik, Muharrem Celik, Bulent Aydemir, Handan Tanrıkulu, Tamer Okay, Nurşen Tanrikulu
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • Pericardial Diseases
    David M. Dudzinski, Gary S. Mak, Judy W. Hung
    Current Problems in Cardiology.2012; 37(3): 75.     CrossRef
  • Epidemiology, diagnosis and therapy of neoplastic pericarditis
    Chiara Lestuzzi
    Journal of Cardiovascular Echography.2011; 21(2): 86.     CrossRef
  • Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment
    Mark A. Lewis, Andrea Wahner Hendrickson, Timothy J. Moynihan
    CA: A Cancer Journal for Clinicians.2011; 61(5): 287.     CrossRef
  • 12,102 View
  • 94 Download
  • 50 Crossref
Close layer
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity
Ho Sup Lee, Chang Bae Son, Seong Hoon Shin, Yang Soo Kim
Cancer Res Treat. 2008;40(3):121-126.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.121
AbstractAbstract PDFPubReaderePub
Purpose

Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.

Materials and Methods

Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.

Results

Of the 86 participants (mean age, 48.5 years; range 20~65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.

Conclusions

The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.

Citations

Citations to this article as recorded by  
  • Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
    Ling-Ming Tseng, Fang Ming Chen, Shou-Tung Chen, Fiona Tsui-Fen Cheng, Tsu-Yi Chao, Ming-Shen Dai, Woei-Yau Kao, Ming-Hsin Yeh, Dar-Ren Chen, Liang-Chih Liu, Hewi Chung Wang, Hong-Tai Chang, Being Whey Wang, Jyh-Cherng Yu, Shin Cheh Chen, Guo-Shiou Liao,
    Oncology Research and Treatment.2024; 47(10): 484.     CrossRef
  • Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways
    Di Zhao, Xin Jiang, Xinxin Meng, Dandan Liu, Yanwei Du, Lijing Zhao, Hongyu Jiang
    Dose-Response.2023;[Epub]     CrossRef
  • Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka
    Jayasinghe Arachchige Nirosha Sandamali, Ruwani Punyakanthi Hewawasam, Madappuli Arachchige Chaminda Sri S Fernando, Kamani Ayoma Perera Wijewardana Jayatilaka
    BMC Cancer.2023;[Epub]     CrossRef
  • Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope
    Rishabh Mittal, Sarath Krishnan M P, Rahul Saxena, Ananyan Sampath, Bela Goyal
    Cancer Treatment and Research Communications.2023; 36: 100750.     CrossRef
  • Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
    Xinxin Zhang, Yuxi Sun, Yanli Zhang, Fengqi Fang, Jiwei Liu, Yunlong Xia, Ying Liu
    Journal of Cardiovascular Development and Disease.2022; 9(11): 372.     CrossRef
  • Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial
    Farina Hellmann, Swantje Völler, Miriam Krischke, David Jamieson, Nicolas André, Gianni Bisogno, Alan Boddy, Georg Hempel
    European Journal of Drug Metabolism and Pharmacokinetics.2020; 45(3): 413.     CrossRef
  • Cardiotoxicity of Anthracyclines
    Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla
    Frontiers in Cardiovascular Medicine.2020;[Epub]     CrossRef
  • The Role of Biomarkers in Cardio-Oncology
    Kajaluxy Ananthan, Alexander R. Lyon
    Journal of Cardiovascular Translational Research.2020; 13(3): 431.     CrossRef
  • Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
    Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita
    Revista Romana de Medicina de Laborator.2020; 28(2): 133.     CrossRef
  • Oncologic therapies associated with cardiac toxicities: how to minimize the risks
    Daniela Cardinale, Federica Stivala, Carlo M. Cipolla
    Expert Review of Anticancer Therapy.2019; 19(5): 359.     CrossRef
  • Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
    Rohit Moudgil, Parag A. Parekh
    Heart Failure Reviews.2018; 23(2): 255.     CrossRef
  • Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
    Faisal Imam, Naif O. Al-Harbi, Mohammed M. Al-Harbia, Hesham M. Korashy, Mushtaq Ahmad Ansari, Mohamed M. Sayed-Ahmed, Mahmoud N. Nagi, Muzaffar Iqbal, Md. Khalid Anwer, Imran Kazmi, Muhammad Afzal, Saleh Bahashwan
    Cardiovascular Toxicology.2017; 17(1): 58.     CrossRef
  • Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
    Daniela Cardinale, Gina Biasillo, Michela Salvatici, Maria Teresa Sandri, Carlo Maria Cipolla
    Expert Review of Molecular Diagnostics.2017; 17(3): 245.     CrossRef
  • Alternative Biomarkers for Combined Biology
    Yong-Hyun Kim, Jennifer Kirsop, Wai Hong Wilson Tang
    Heart Failure Clinics.2017; 13(2): 381.     CrossRef
  • Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts
    Gina Biasillo, Carlo M. Cipolla, Daniela Cardinale
    Current Oncology Reports.2017;[Epub]     CrossRef
  • Cardiovascular Complications of Cancer Therapy
    Hui-Ming Chang, Rohit Moudgil, Tiziano Scarabelli, Tochukwu M. Okwuosa, Edward T.H. Yeh
    Journal of the American College of Cardiology.2017; 70(20): 2536.     CrossRef
  • Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
    Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla
    CA: A Cancer Journal for Clinicians.2016; 66(4): 309.     CrossRef
  • Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
    Hesham M. Korashy, Ibraheem M. Attafi, Mushtaq A. Ansari, Mohammed A. Assiri, Osamah M. Belali, Sheik F. Ahmad, Ibrahim A. AL-Alallah, Fawaz E.Al Anazi, Abdulqader A. Alhaider
    Toxicology Letters.2016; 252: 50.     CrossRef
  • Role of biomarkers in monitoring antiblastic cardiotoxicity
    Giuseppina Novo, Christian Cadeddu, Vincenzo Sucato, Pasquale Pagliaro, Silvio Romano, Carlo G. Tocchetti, Concetta Zito, Luca Longobardo, Savina Nodari, Maria Penco
    Journal of Cardiovascular Medicine.2016; 17: e27.     CrossRef
  • Biomarkers and Cancer Therapy-Related Cardiac Dysfunction
    Prateek Sharma, Mahin Rehman, Javed Butler, Michelle W. Bloom
    Current Cardiovascular Risk Reports.2016;[Epub]     CrossRef
  • The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy
    Christine Henri, Therese Heinonen, Jean-Claude Tardif
    Biomarkers in Cancer.2016; 8s2: BIC.S31798.     CrossRef
  • Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity
    YA-DI WANG, SU-XIAN CHEN, LI-QUN REN
    Oncology Letters.2016; 11(5): 3483.     CrossRef
  • Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells
    Hesham Mohamed Korashy, Hani A. Al-Suwayeh, Zaid H. Maayah, Mushtaq Ahmad Ansari, Sheikh Fayaz Ahmad, Saleh A. Bakheet
    Cardiovascular Toxicology.2015; 15(1): 41.     CrossRef
  • Cardiotoxicity due to Chemotherapy: the Role of Biomarkers
    Patrick L. Stevens, Daniel J. Lenihan
    Current Cardiology Reports.2015;[Epub]     CrossRef
  • Cardiac Complications of Chemotherapy: Role of Biomarkers
    Alessandro Colombo, Maria T. Sandri, Michela Salvatici, Carlo M. Cipolla, Daniela Cardinale
    Current Treatment Options in Cardiovascular Medicine.2014;[Epub]     CrossRef
  • Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity
    Eric S. Christenson, Theodore James, Vineet Agrawal, Ben H. Park
    Clinical Biochemistry.2014;[Epub]     CrossRef
  • BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography
    Dorthe Skovgaard, Philip Hasbak, Andreas Kjaer, Claudio Moretti
    PLoS ONE.2014; 9(5): e96736.     CrossRef
  • Using Cardiac Biomarkers and Treating Cardiotoxicity in Cancer
    Alessandro Colombo, Daniela Cardinale
    Future Cardiology.2013; 9(1): 105.     CrossRef
  • Exaggerated NT‐proBNP Production in Patients With Hematologic Malignancies: A Case Series
    Aileen Andreu, Maya Guglin
    Congestive Heart Failure.2012; 18(6): 333.     CrossRef
  • Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience
    Erkan Dogan, Hikmet Yorgun, Ibrahim Petekkaya, Necla Ozer, Kadri Altundag, Yavuz Ozisik
    Medical Oncology.2012; 29(5): 3232.     CrossRef
  • NT-ProBNP and cardiac troponin I in virulent canine babesiosis
    Remo Lobetti, Robert Kirberger, Ninette Keller, Frank Kettner, Eran Dvir
    Veterinary Parasitology.2012; 190(3-4): 333.     CrossRef
  • Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
    Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi, Giuseppe Toglia
    Journal of Cardiovascular Echography.2011; 21(1): 32.     CrossRef
  • Role of biomarkers in cardioncology
    Daniela Cardinale, Michela Salvatici, Maria T. Sandri
    Clinical Chemistry and Laboratory Medicine (CCLM).2011;[Epub]     CrossRef
  • Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
    Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
    Journal of Controlled Release.2010; 142(1): 101.     CrossRef
  • Cardiac Involvement in Patients with Hematologic Malignancies
    Alessandro Allegra, Andrea Alonci, Sabina Russo, Antonino Cannavò, Giuseppa Penna, Arianna D'Angelo, Giacomo Bellomo, Caterina Musolino
    Journal of Investigative Medicine.2010; 58(7): 859.     CrossRef
  • 10,609 View
  • 80 Download
  • 35 Crossref
Close layer
Case Report
A Case of Intracardiac Lymphoma as a Presentation of Non Hodgkin's Lymphoma
Gun Lee, Kyung Sam Cho, Suk Chon, Young Hee Joung, Cheon Woong Choi, Si Young Kim, Hwi Joong Yoon
Cancer Res Treat. 2001;33(5):438-441.   Published online October 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.5.438
AbstractAbstract PDF
Lymphomatous involvement of the heart is extremely rare at initial diagnosis and presentation of malignant lymphoma. Worldwide, only a few cases have been diagnosed and treated during life and only four cases were diagnosed before death in Korea. We report a case of non-Hodgkin's lymphoma with two right atrial masses detected by chest computed tomography and transesophageal echocardiography. The patient was an 80 year- old man and the presenting symptoms included generalized weakness, weight loss, constipation and low abdominal pain. For diagnosis, the mass of the perinephric area was biopsied under ultrasonographic guidance, and pathologically it was determined to be malignant lymphoma, diffuse large B cell type. The patient was treated with continuous low dose cyclophosphamide and prednisolone vice standard chemotherapy because of advanced age and renal dysfunction. After 2 months of treatment the masses in the atrium and the intraabdominal masses disappeared.
  • 3,828 View
  • 26 Download
Close layer
Original Articles
A Case of Cardiac Metastasis of Chondrosarcoma
Seung Park Yoo, Bo Yun Chung, Ki Chan Kim, Yeul Hong Kim, Jeong Sik Park, Hyo Jin Lee
J Korean Cancer Assoc. 1994;26(2):345-351.
AbstractAbstract PDF
Metastatic cardiac cancers are more prevalent than generally realized. So prompt recognition is mandatory if any cardiovascular manifestations develop in a patient with a malignant lesion elswhere in the body. Sixty-five year old male patient who had past history of resected chondrosarcoma on the 10th rib of left side presented as a local recurrence and dyspnea. Chest C-T findings demonstrated thrombose on right atrium and superior vena cava. Two-dimensional echocardiographic study showed mild pericardial effusion with a small mass attached to the visceral pericardium and a huge mass occupying nearly entire right atrial chamber with extension to superior vena cava. These findings are suggestive of cardiac metastasis of chon- drosarcoma.
  • 2,801 View
  • 17 Download
Close layer
Clincial Analysis of Gastric Cardia Cancer
Jin Pok Kim, Hwan Young Yoo, Song Cheol Kim, Han Kwang Yang
J Korean Cancer Assoc. 1994;26(3):361-369.
AbstractAbstract PDF
Gastric cardia cancers comprise gastric cancers which involve stomach of distal 2cm from gastroesophageal junction. It has been reported that cardia cancer has relatively poorer prog- nosis than gastric cancer of the other sites. To evaluate clinicopathological characteristics of gastric cardia cancer and to determine prognostic factors, we analyzed retrospectively 198 pa- tients who underwent operations for gastric cardia cancers between 1970 and l991 and had the following results. Gasric resection was performed in 176 patients. The ratio of gastric cardia cancer to gastric cancers of the other sites was slightly decreased in 1980s than in l970s (over- all 3.8% of gastric cancers). Gastric cardia cancer had poorer 5-year survival rate than those of gastric cancers of other sites (34.2% for cardia, 38.5% for fundus, 54.1% for body, 48.9% for an- trum). In cardia cancer, 2.5% was early gastric cancer, 89.3% had more than serosal invasion, 66. 5% had positive lymph node involvement and 75.2% were in stage III 4 IV. There was esophageal involvement in 33.5%; despite clear proximal resection mergin on frozen biopsies, there were positive resection margin of 21.4% (3/14) in cases with resection margin of less than 2 cm and 3.7% (6/162) in cases with resection margin of 2cm or more than 2cm (p<0.05, Fisher's exact test). These results suggest that the length of proximal resection margin should be at least 2 cm to get a cancer-free proximal resection margin in gastric cardia cancer. Multivariate analysis revealed that depth of invasion, length of proximal resection margin and lymph node metastasis were significant prognostic factors. We conclude that poorer prognosis of gastric cardia cancer is due to more advanced stage at the time of diagnosis. Therefore, to improve the survival of gastric cardia cancer, better means of early diagnosis should be developed.
  • 2,956 View
  • 25 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP